Shares in UK-based Allergy Therapeutics have taken a dive after the firm’s immunotherapy for birch pollen allergy failed to hit targets in a late-stage trial.
News
Groundbreaking study finds optimum dosage of IV iron for kidney patients
New iron-trial results have paved the way for improved haemodialysis treatment.
Lewy Body Society grants £1 million for dementia research
The Lewy Body Society has announced that the latest recipients of its grant programme will be University of Cambridge, Newcastle University and Imperial College London.
Molecular patterns could better predict breast cancer recurrence
A study has found that molecular patterns could better predict breast cancer recurrence.
CMA drops anti-competitive case against MSD
The CMA has closed its investigation into a suspected anti-competitive discount scheme by MSD, findings no grounds for action.
EU regulators expand Praluent’s label
European regulators have approved a new indication for Regeneron and Sanofi’s Praluent, allowing its use to cut cardiovascular risk in adults with established atherosclerotic CV disease (ASCVD).
NHS ‘overwhelmed despite best efforts of staff’
NHS England has published NHS performance statistics for February, which show that the service is continuing to struggle under pressure.
Uveal melanoma study announced
Researchers have announced a study to identify new treatments for uveal melanoma.
Merck and Iktos to form AI alliance
Merck has announced an AI-based collaboration with Iktos.
CCGs failing to demonstrate value for money
As many as 38% of NHS bodies such as clinical commissioning groups (CGCs) and hospital trusts are failing to show that the money they spend is good value, according to a report by the Public Accounts Committee.
King’s College signs mental health deal with Hong Kong uni
King’s College London and The Chinese University of Hong Kong have renewed their long-standing partnership but also agree to work on mental health as part of the collaboration.
Study warns of disinfectant use in hospitals
A new study has warned that the use of disinfectants to clean and control infections in hospitals should be regulated in the same way that prescribing antibiotics is, to help combat antimicrobial resistance.
New lung cancer indication for Keytruda combo OK’d in EU
MSD’s anti-PD-1 therapy Keytruda has been approved for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for first-line treatment of adults with metastatic squamous non-small cell lung cancer (NSCLC).
UK breast cancer patients win early access to Tecentriq/nab-paclitaxel
Adults in the UK with PD-L1 positive, unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) have won early access to Roche’s immunotherapy Tecentriq in combination with nab-paclitaxel chemotherapy.
EC extends license for Roche/Chugai’s Hemlibra
The European Commission has approved Roche and Chugai Pharma UK’s Hemlibra for the prevention of bleeding episodes in people with severe haemophilia A without factor VIII inhibitors, expanding the drug’s treatment scope.
